This article reviews recent immunotherapy studies of Type 1 Diabetes (T1D) which is an autoimmune disease. Researchers show that injecting human proinsulin peptides can safely modulate the immune system and affect beta-cell function in Type 1 Diabetes, but oral insulin consumption does not reduce the onset of Type 1 Diabetes in individuals at the early stage of the disease.

Comments & Peer Review

Must Read